Building a More Connected DSMB: Better Integrating Ethics Review and Safety Monitoring

Accountability in Research

Volumn 22, Issue 2, 2015, Pages 81-105

  Eckstein, Lisa ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

clinical trials; data monitoring; Data Safety and Monitoring Boards; human subjects protection; Institutional Review Board; research ethics

Indexed keywords

CONFIDENTIALITY; DECISION MAKING; DRUG INDUSTRY; ETHICS; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN EXPERIMENT; NATIONAL HEALTH ORGANIZATION; PATIENT SAFETY; PROFESSIONAL STANDARD; RESEARCH ETHICS; UNITED STATES;

CLINICAL TRIALS DATA MONITORING COMMITTEES; CONFIDENTIALITY; DECISION MAKING; DRUG INDUSTRY; ETHICS COMMITTEES, RESEARCH; ETHICS, RESEARCH; HUMAN EXPERIMENTATION; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); PATIENT SAFETY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84910130068     PISSN: 08989621     EISSN: 15455815     Source Type: Journal    
DOI: 10.1080/08989621.2014.919230     Document Type: Article

References (49)

1. Anderson, E. E. (2006). A qualitative study of non-Affiliated, non-scientist Institutional Review Board members. Accountability in Research, 13(2):135–155.
2. Buchanan, D. and Miller, F. G. (2005). Principles of early stopping of randomized trials for efficacy: A critique of equipoise and an alternative nonexploitation ethical framework. Kennedy Institute of Ethics Journal, 15(2):161–178.
3. Califf, R. M., Morse, M. A., Wittes, J., Goodman, S. N., Nelson, D. K., DeMets, D. L, Iafrate, R. P., and Sugarman, J. (2003). Toward protecting the safety of participants in clinical trials. Controlled Clinical Trials, 24(3):256–271.
4. DeMets, D. L. and Friedman, L. M. (2006). The data monitoring experience in the cardiac arrhythmia trial: The need to be prepared early. In: Data Monitoring in Clinical Trials: A Case Studies Approach. DeMets, D. L., Furberg, C. D., and Friedman, L. M. (eds.). New York: Springer; pp. 198–208.
5. DeMets, D. L., Fost, N., and Powers, M. (2006). An Institutional Review Board dilemma: Responsible for safety monitoring but not in control. Clinical Trials, 3(2):142–148.
6. DeMets, D. L., Furberg, C. D., and Friedman, L. M. (2006). Data Monitoring in Clinical Trials: A Case Studies Approach. New York: Springer.
7. Department of Health and Human Services. (1996). Waiver of Informed Consent Requirements in Certain Emergency Research. Federal Register.
8. Department of Health and Human Services Office of Inspector General. (2013). Data and Safety Monitoring Boards in NIH Clinical Trials: Meeting Guidance, But Facing Some Issues. OEI-12-11-00070. Available at https://oig.hhs.gov/oei/reports/oei-12-11-00070.pdf. Last accessed August 9, 2013.
9. Dixon, D. O., Weiss, S., Cahill, K., Fox, L., Love, J., McNamara, J., and Soto-Torres, L. (2011). Data and safety monitoring policy for National Institute of Allergy and Infectious Diseases clinical trials. Clinical Trials, 8(6):727–735.
10. Droppert, P. (2012). J&J Prostate Cancer Trial Shouldn’t Have Been Stopped Early. Xconomy. Available at http://www.xconomy.com/national/2012/06/03/jj-prostate-cancer-trial-shouldnt-have-been-stopped-early/. Last accessed September 26, 2013.
11. Duncan, W., Smith, A. N., Freedman, L. S., Alderson, M. R., Arnott, S. J., Bleehen, N. M., Bond, W. H. Crowther, D., Deeley, T. J., Duthie, H. L., Dykes, P. W., Fielding, L. P., Flatman, G. E., Goligher, J. C., Hawley, P. R., Hughes, L. E., Jolin, C. a. F., Koriech, O. M., Morson, B. C., Oates, G. D., Peckham, M. J., Sandland, M. R., Schofield, P. F., Slack, W., Slaney, G., Smith, J. a. R., Scott, J., Whitehouse, J. M. A., Wrigley, P. F. M., and York-Maso, A. (1984). The evaluation of low dose pre-operative X-ray therapy in the management of operable rectal cancer: Results of a randomly controlled trial. British Journal of Surgery, 71(1):21–25.
12. Ellenberg, S. and Siegel, J. P. (2006). FDA and clinical trial data monitoring committees. In: Data Monitoring in Clinical Trials: A Case Studies Approach. DeMets, D. L., Furberg, C. D., and Friedman, L. M. (eds.). New York: Springer.
13. Ellenberg, S. S., Fleming, T. R., and DeMets, D. L. (2002). Data Monitoring Committees in Clinical Trials: A Practical Perspective. Statistics in Practice. Chichester, West Sussex; Hoboken, N.J.: J. Wiley.
14. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. (1998). Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute, 90(18):1371–1388.
15. Fleming, T. R., Ellenberg, S., and DeMets, D. (2002). Monitoring clinical trials: Issues and controversies regarding confidentiality. Statistics in Medicine, 21(19):2843–2851.
16. Fleming, T. R., Sharples, K., McCall, J., Moore, A., Rodgers, A., and Stewart, R. (2008). Maintaining confidentiality of interim data to enhance trial integrity and credibility. Clinical Trials, 5(2):157–167.
17. Food and Drug Administration. (2006). Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees. Available at http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM127073.pdf. Last accessed August 13, 2013.
18. Freedman, B. (1987). Equipoise and the ethics of clinical research. New England Journal of Medicine, 317(3):141–145.
19. Gordon, V. M., Sugarman, J., and Kass, N. (1998). Toward a more comprehensive approach to protecting human subjects: The interface of data safety monitoring boards and Institutional Review Boards in randomized clinical trials. IRB: Ethics and Human Research 20(1):1.
20. Grant, A. M., Altman, W. H., Babiker, A. B., Campbell, M. K., Clemens, F. J., Darbyshire, J. H., Elbourne, D. R., McLeer, S. K., Parmar, M. K. B., Pocock, S. J., Spiegelhalter, D. J., Sydes, M. R., Walker, A. E., and Wallace, S. A. (2005). Issues in data monitoring and interim analysis of trials. Health Technology Assessment (Winchester, England), 9(7):1–238.
21. Greenberg, B. G. (1988). Organization, review, and administration of cooperative studies (Greenberg Report): A report from the Heart Special Project Committee to the National Advisory Heart Council, May 1967. Controlled Clinical Trials, 9(2):137–148.
22. Herson, J. (2009). Data and Safety Monitoring Committees in Clinical Trials. Chapman & Hall/CRC Biostatistics Series 30. Boca Raton, FL: Chapman & Hall/CRC.
23. Hulley, S. B., Grady, D., Vittinghoff, E., and Williams, O. D. (2006). Consideration of Early Stopping and Other Challenges in Monitoring the Heart and Estrogen/Progestin Replacement Study. In Data Monitoring in Clinical Trials: A Case Studies Approach. DeMets, D. L., Furberg, C. D., and Friedman, L. M. (eds.). New York: Springer; pp. 236–247.
24. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. (1996). Guideline for Good Clinical Practice E6 (R1). Available at http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf. Last accessed April 20, 2013.
25. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. (1998). Guideline for Good Clinical Practice: Statistical Principles for Clinical Trials (E9). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf. Last accessed August 13, 2013.
26. Korn, E. L. and Freidlin, B. (2011). Inefficacy interim monitoring procedures in randomized clinical trials: The need to report. The American Journal of Bioethics, 11(3):2–10.
27. Lilford, R. J., Braunholtz, D., Edwards, S., and Stevens, A. (2001). Monitoring clinical trials—Interim data should be publicly available. BMJ, 323(7310):441–442.
28. Malmqvist, E., Juth, N., Lynöe, N., and Helgesson, G. (2011). Early stopping of clinical trials: Charting the ethical terrain. Kennedy Institute of Ethics Journal, 21(1):51–78.
29. Miller, A. B., Buring, J., and Williams, O. D. (2006). Stopping the carotene and retinole efficacy trial: The viewpoint of the Safety and Endpoint Monitoring Committee. In: Data Monitoring in Clinical Trials: A Case Studies Approach. DeMets, D. L., Furberg, C. D., and Friedman, L. M. (eds.). New York: Springer; pp. 220–227.
30. Moher, D., Hopewell, S., Schulz, K. F, Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., and Altman, D. G. (2010). CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. BMJ, 340(March23):c869–c869.
31. Morse, M. A. and Califf, R. M. (2001). Monitoring and ensuring safety during clinical research. JAMA, 285(9):1201–1205.
32. National Institutes of Health. (1998). NIH Policy for Data and Safety Monitoring. Available at http://grants.nih.gov/grants/guide/notice-files/not98-084.html. Last accessed April 25, 2013.
33. Office of the Inspector General. (1998). Institutional Review Boards: A Time for Reform. Available at http://oig.hhs.gov/oei/reports/oei-01-97-00193.pdf. Last accessed May 3, 2013.
34. Pocock, S., Wilhelmsen, L., Dickstein, K., Francis, G., and Wittes, J. (2004). The data monitoring experience in the MOXCON trial. European Heart Journal, 25(22):1974–1978.
35. Pogue, J. and Yusuf, S. (2006). Data monitoring in the randomized evaluation of strategies for left ventricular dysfunction pilot study: When reasonable people disagree. In: Data Monitoring in Clinical Trials: A Case Studies Approach. DeMets, D. L., Furberg, C. D., and Friedman, L. M. (eds.). New York: Springer; pp. 330–336.
36. Redmond, C. K., Constantino, J. P., and Colton, T. (2006). Challenges in monitoring the breast cancer prevention trial. In Data Monitoring in Clinical Trials: A Case Studies Approach. DeMets, D. L., Furberg, C. D., and Friedman, L. M. (eds.). New York: Springer; 118–135.
37. Rider, W. D., Palmer, A., Mahoney, L. J., and Robertson, C.T. (1977). Preoperative irradiation in operable cancer of the rectum: Report of the Toronto trial. Canadian Journal of Surgery, 20(4):335–338.
38. Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., Carles, J., Mulders, P. F. A, Basch, E., Small, E., Saad, F., Schrijvers, D., Van Poppel, H., Gerritsen, W. R., Flaig, T. W., George, D. J., Yu, E. Y., Efstathiou, E., Pantuck, A., Winquist, E., Higano, C., Taplin, M., Park, Y., Kheoh, T., Griffin, T., Scher, H. L., and Rathkopf, D. E. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine, 368(2):138–148.
39. Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C., de Souza, P., Fizazi, K., Mainwaring, P. N., Rodriguez, J. M., Ng, S., Carles, J., Mulders, P., Kheoh, T., Griffin, T. W., Small, E. J., Scher, H. I., and Rathkopf, D. E. (2012). Interim Analysis (IA) results of COU-AA-302, a randomized, Phase III Study of Abiraterone Acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). In: Clinical Science Symposium, New Paradigms for Hormone Therapy in Prostate Cancer. Chicago. Available at http://meetinglibrary.asco.org/content/95300-114. Last accessed September 29, 2013.
40. Sengupta, S. and Lo, B. (2003). The roles and experiences of nonaffiliated and non-scientist members of Institutional Review Boards. Academic Medicine: Journal of the Association of American Medical Colleges, 78(2):212–218.
41. Shah, S. K., Dawson, L., Dixon, D. O., and Lie, R. K. (2011). Should sponsors and DSMBs share interim results across trials? Journal of Acquired Immune Deficiency Syndromes, 58(5):433–435.
42. Slutsky, A. S. and Lavery, J. V. (2004). Data safety and monitoring boards. The New England Journal of Medicine, 350(11):1143–1147.
43. Sydes, M. R., Altman, D. G., Babikera, A. B., Parmar, M. K., and Spiegelhalter, D. J. (2004). Reported use of data monitoring committees in the main published reports of randomized controlled trials: A cross-sectional study. Clinical Trials, 1(1):48–59.
44. Taylor, H. A., Chaisson, L., and Sugarman, J. (2008). Enhancing communication among data monitoring committees and Institutional Review Boards. Clinical Trials, 5(3):277–282.
45. Tereskerz, P. M., Guterbock, T. M., Kermer, D. A., and Moreno, J. D. (2011). An opinion and practice survey on the structure and management of data and safety monitoring boards. Accountability in Research, 18(1):1–30.
46. Thomas, D. E. and Snappin, S. (2002). Guidelines for Data and Safety Monitoring Boards. Merck. Available at: http://dida.library.ucsf.edu/lawsuits.jsp. Last accessed July 1, 2014.
47. Wheatley, K. and Clayton, D. (2003). Be skeptical about unexpected large apparent treatment effects: The case of an MRC AML12 randomization. Controlled Clinical Trials, 24(1):66–70.
48. Wittes, J. (1993). Behind closed doors: The data monitoring board in randomized clinical trials. Statistics in Medicine, 12(5–6):419–424.
49. World Medical Association. (2013). World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA, 310(20):2191–2194.